Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
| MarketCap | 10.5B |
|---|---|
| PE Ratio | -10.2 |
| PEG Ratio | 1.2 |
| P/B | |
| P/S (ttm) | 1.3 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 6% |
| Held by Institutions % | 72% |
| 1 Day Vol Adjusted Return | -0.5 |
| 1 Month Vol Adjusted Return | -0.1 |
| 3 Month Vol Adjusted Return | -4.1 |
| 6 Month Vol Adjusted Return | 6.6 |
| 20 Days SMA Price ZScore | 0.5 |
| 50 Days SMA Price ZScore | -0.6 |
| 12 -26 Days PPO | -0.7 |
| 1 Month Average Short Volume Ratio | 26.9 |
| 1 Day Volume Change ZScore | -0.5 |
| 1 Month Daily Vol | 2.2 |
Stock news
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the second of two Phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with m
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2021 financial results on Tuesday, Aug. 3, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Bausch Health Industries Inc. said Thursday it is reducing its debt by $150 million through the redemption of outstanding bonds using cash from operations. The company, the former Valeant, has regularly made such moves as it works to reduce a debt burden that stood at $23.7 billion at the end of March, according to FactSet data. Most of that was taken on as Valeant when it went on an acquisition spree. The bonds to be redeemed are the company's 6.125% notes that mature on Aug. 2. Shares were dow
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $150 million through the redemption of outstanding senior notes, using cash generated from operations.
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S. launch of expanded parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses. The expansion, which includes the addition of -2.25D and -2.75D cylinder power parameters, will be part of the company's standard offering of the lens and will extend the power range available to eye care professionals and their patients who have both astigm
Bausch Health Companies Inc. (NYSE/TSX: BHC)("Bausch Health," the "Company" or the "Offeror") today announced that it has extended the expiration date for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the "Notes"). The Offeror's obligation to accept and pay for the Notes remains subject to the terms of the Tender Offer as described in the Offer to Purchase, dated May 24, 2021 (the "Offer to Purchase
In this article we will take a look at the top stocks to invest in according to Jeffrey Ubben’s ValueAct Capital. If you want to skip our detailed analysis of Ubben’s history, investment philosophy, and hedge fund performance, go directly to the Top 5 Stocks to Invest In According to Jeffrey Ubben’s ValueAct Capital. Jeffrey […]